Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase IIb Multi-Regional Clinical Trial of AP306 for Hyperphosphatemia Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5008843_CN08843_0